§ 22 §2671 — Definitions

As used in this chapter, unless the context otherwise indicates, the following terms have the following meanings.
1.
Eligible patient.
"Eligible patient" means a person who has:
2.
Investigational drug, biological product or device.
"Investigational drug, biological product or device" means a drug, biological product or device that has successfully completed Phase I of a United States Food and Drug Administration-approved clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in such a clinical trial.
3.
Terminal illness.
"Terminal illness" means a disease or condition that, without life-sustaining measures, will soon result in death or in a state of permanent unconsciousness from which recovery is unlikely.
4.
Treating physician.
"Treating physician" means a physician who has primary responsibility for the care of a patient and treatment of that patient's terminal illness.
5.
Written, informed consent.
"Written, informed consent" means a written document signed by a patient or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian of the patient. The document must be attested by the patient's treating physician and a witness and include the following information:

Legislative History

PL 2015, c. 418, §1 (NEW).